IFRX N logo

InflaRx N.V.BMV:IFRX N Stock Report

Market Cap Mex$5.4b
Share Price
n/a
1Yn/a
7D0%
Portfolio Value
​
View

InflaRx N.V.

BMV:IFRX N Stock Report

Market Cap: Mex$5.4b

InflaRx (IFRX N) Stock Overview

A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More details

IFRX N fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue (€-10K)

Shares are highly illiquid

Earnings are forecast to decline by an average of 5.3% per year for the next 3 years

Shareholders have been substantially diluted in the past year

+ 1 more risk

IFRX N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW445,219 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
445,219 investors already sharing narratives
View all narratives

InflaRx N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for InflaRx
Historical stock prices
Current Share PriceUS$35.00
52 Week HighUS$35.00
52 Week LowUS$22.00
Beta2.54
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.24%

Recent News & Updates

Recent updates

Shareholder Returns

IFRX NMX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how IFRX N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how IFRX N performed against the MX Market.

Price Volatility

Is IFRX N's price volatile compared to industry and market?
IFRX N volatility
IFRX N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: IFRX N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine IFRX N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200765Niels Riedemannwww.inflarx.de

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.

InflaRx N.V. Fundamentals Summary

How do InflaRx's earnings and revenue compare to its market cap?
IFRX N fundamental statistics
Market capMex$5.36b
Earnings (TTM)-Mex$774.50m
Revenue (TTM)n/a
9,999x
P/S Ratio
-6.9x
P/E Ratio

Is IFRX N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IFRX N income statement (TTM)
Revenue-€10.10k
Cost of Revenue€4.86m
Gross Profit-€4.87m
Other Expenses€34.28m
Earnings-€39.14m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin48,201.61%
Net Profit Margin387,532.07%
Debt/Equity Ratio0%

How did IFRX N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 21:50
End of Day Share Price 2026/08/19 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

InflaRx N.V. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.